Temporary Disabled. :) please Go back Frexalimab - Wikipedia www.fgks.org » Address: [go: up one dir, main page] Include Form Remove Scripts Accept Cookies Show Images Show Referer Rotate13 Base64 Strip Meta Strip Title Session Cookies Home Random Nearby Log in Settings Donate About Wikipedia Disclaimers Search Frexalimab Article Talk Language Watch Edit This is an old revision of this page, as edited by Mahmoudalrawi (talk | contribs) at 14:43, 8 October 2023. The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.Revision as of 14:43, 8 October 2023 by Mahmoudalrawi (talk | contribs)(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff) Frexalimab is an second-generation monoclonal antibody[1] for the treatment of relapsing multiple sclerosis, under developement by Sanofi.[2] FrexalimabMonoclonal antibodyTypeWhole antibodyTargetCD40 ligandClinical dataAHFS/Drugs.comMonographLicense data US DailyMed: Abelacimab US FDA: Abelacimab Legal statusLegal status Investigational IdentifiersChemSpidernoneKEGGD10821 Y Mechanism of action It is a CD40 ligand inhibitor.[2][1] See also Medicine portal Antibody Monoclonal antibody Immunology References ^ a b Media Update: Anti-CD40L antibody frexalimab slows new brain lesions in multiple sclerosis ^ a b Media Update: Sanofi presents new data from robust MS clinical pipeline exploring multiple approaches to address important unmet patient needs Portal: Medicine This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.vte
This is an old revision of this page, as edited by Mahmoudalrawi (talk | contribs) at 14:43, 8 October 2023. The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.
Frexalimab is an second-generation monoclonal antibody[1] for the treatment of relapsing multiple sclerosis, under developement by Sanofi.[2]
It is a CD40 ligand inhibitor.[2][1]
This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.